Navigation Links
China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference
Date:11/15/2010

China Biologic Products to Present at Brean Murray, Carret 2010 China Growth... -- TAI'AN, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference

 

TAI'AN, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that the Company's management will present at the upcoming Brean Murray, Carret & Co. 2010 China Growth Conference. Date:

November 17, 2010 Time:

09:20 a.m. ESTPresenter:

Ming Yin, Vice President - Finance Location:

Track IIThe Millennium Broadway Hotel145 West 44th StreetNew York, New York 10036The Brean Murray, Carret & Co. 2010 China Growth Conference is a two-day conference (November 17-18, 2010) that consists of 25-minute presentation slots followed by 10-minutes of open floor Q&A sessions with institutional investors. Senior management of presenting companies, industry experts, and institutional investors will receive a unique and comprehensive view of China from a global perspective. China Biologic's management will be available for 1x1 meetings before and after the Company's presentation.

About China Biologic Products, Inc.China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biological Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical company in China. The Company is a fully integrated biological products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

Company Contact:Mr. Ming YinVice President - FinanceChina Biologic Products, Inc.Tel: +86-851-3605846Email: IR@chinabiologic.comwww.chinabiologic.com Investor Relations Contact:Mr. Crocker Coulson, President CCG Investor RelationsPhone: +1 (646) 213-1915Email: crocker.coulson@ccgir.comwww.ccgirasia.com
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics Appoints New Chief Operating Officer
2. China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results
3. China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9
4. Verenium Announces Regulatory Approval for Purifine® PLC in China
5. China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
6. Reportlinker Adds Industrial Biotechnology China News 1009
7. According to Opurity, Feds Put U.S. Consumers at Risk: PTO Bureaucrats Refuse to Approve Vitamin Companys China-Free Trademark
8. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
9. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
10. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
11. China-Biotics Hosted its First Investor Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... PHOENIX and NEW YORK ... announced the near completion of their $7M Series B ... on top of the $3.5M led by Mesa Verde ... of 2016.  These resources will be directed towards further ... Test, PCDx, a comprehensive genomic profiling test and expanding ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
(Date:2/15/2017)... FRANCISCO , 15. Februar 2017  Trianni, ... Janssen Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die ... ihrer Klasse führenden Plattform für die Entdeckung monoklonaler ... durch ihr neuartiges chimäres Gensegmentdesign aus, das ... an humanen Antikörpern bietet und das für die ...
(Date:2/15/2017)... 15, 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter and full year ended December ... year for Vanda as we continued to demonstrate ... long-term exclusivity for Fanapt," said Mihael H. Polymeropoulos, ... emerging pipeline with important 2017 milestones underscores Vanda,s ...
Breaking Biology Technology:
(Date:1/21/2017)... Research and Markets has announced the addition of the ... ... voice recognition biometrics market to grow at a CAGR of 19.36% ... present scenario and the growth prospects of the global voice recognition ... considers the revenue generated from the sales of voice recognition biometrics ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
(Date:1/18/2017)... Minn. , Jan. 18, 2017 ... technology company that supports the entire spectrum of ... has been another record-breaking year for the organization ... market interest in MedNet,s eClinical products and services. ... the tremendous marketplace success of iMedNet ...
Breaking Biology News(10 mins):